2-methyl-2-(4-methylamino-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propionic acid ethyl ester | 851077-24-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-2-(4-methylamino-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propionic acid ethyl ester
• 英文别名: ethyl 2-methyl-2-[[4-(methylamino)-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]propanoate
• CAS: 851077-24-2
• 化学式: C₁₇H₂₅NO₃
• 分子量: 291.39
• InChiKey: MALKPKAPAVZEMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 2-methyl-2-(4-methylamino-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propionic acid ethyl ester 、 3-chloromethyl-2-methyl-6-(4-trifluoromethyl-phenyl)-pyridine 以to give 2-methyl-2-(4-{methyl-[2-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ylmethyl]-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propionic acid ethyl ester, which的产率得到2-Methyl-2-(4-{methyl-[2-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ylmethyl]-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propionic acid ethyl ester
  参考文献：
  名称：

  Benzannelated derivatives, their manufacture and use as pharmaceutical agents

  摘要：

  本发明提供了以下化合物，其中R6和R7分别为R4和R5或R5和R6与它们附着的碳原子一起形成描述中定义的环，X1、X2、Y1至Y4、R1至R13和n如描述中所指定的，并且包括所有对映体和药学上可接受的盐和/或酯。本发明还涉及含有这些化合物的制药组合物，以及它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病的用途的制备方法。

  公开号：

  US20050096336A1

文献信息

• BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1682507A1

  公开（公告）日：2006-07-26
• US7495001B2
  申请人：——

  公开号：US7495001B2

  公开（公告）日：2009-02-24
• [EN] BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS<br/>[FR] COMPOSES A CYCLE BENZENIQUE CONSTITUANT DES ACTIVATEURS DE PPAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005049572A1

  公开（公告）日：2005-06-02

  This invention relates to compounds of the formula (I) wherein R6 and R7 is formula (II) R4 and R5 or R5 and R6 together with the carbon atoms to which they are attached, form a ring as defined in the description and X1, X2, Y1 to Y4, R1 to R13 and n are as specified in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or- PPARα agonists.